Skip to content

Study · Animal study (in vivo) · rat · 1997

3 results

[The pharmacokinetics of the dipeptide analog of piracetam with nootropic activity GVS-111 and of its basic metabolites].

Boĭko SS, Zherdev VP, Dvorianinov AA, Gudasheva TA, Ostrovskaia RU, Voronina TA, Rozantsev GG, Seredenin SB

Eksperimental'naia i klinicheskaia farmakologiia1 Mar 1997Cited by 1 (Europe PMC)

PMID9206571 (opens in a new tab)PepBankPUB-09206571
Publisher pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Pharmacokinetics

    In rats, plasma contained unchanged GWS-111 and three metabolites.

    In plain wordsIn rats, blood plasma contained unchanged GWS-111 and three metabolites.

    Peptide
    Noopept (omberacetam)
    Outcome
    Not applicablePlasma parent compound and metabolites
    Study

    ratn: not reported in source

    Rat pharmacokinetics
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In addition to an unchanged compound three of its metabolites were found in the blood plasma of the rats.
    1 context sentence
    Summary · context
    The pharmacokinetics of a new nootropic dipeptide analog of piracetam-N-phenylacetyl-L-prolylglycine (GWS-111) and its main metabolites were studied in rats by means of high performance liquid chromatography and gas-liquid chromatography.
  2. 02AnimalAnimal study (in vivo)Pharmacokinetics

    In rats, cyclo-Pro-Gly was identified as an active metabolite of GWS-111.

    In plain wordsIn rats, cyclo-Pro-Gly was an active metabolite of GWS-111.

    Peptide
    Noopept (omberacetam)
    Outcome
    Not applicableActive metabolite identity
    Study

    ratn: not reported in source

    Rat pharmacokinetics
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    One of them, cyclo-Pro-Gly was an active metabolite of GWS-111.
    1 context sentence
    Summary · context
    The pharmacokinetics of a new nootropic dipeptide analog of piracetam-N-phenylacetyl-L-prolylglycine (GWS-111) and its main metabolites were studied in rats by means of high performance liquid chromatography and gas-liquid chromatography.

Studies that did not test the peptide alone1

In this study, Noopept (omberacetam) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Noopept (omberacetam).

  1. 03AnimalNot a test of Noopept (omberacetam) aloneAnimal study (in vivo)Pharmacokinetics

    In the rat pharmacokinetic study, GWS-111 showed greater resistance to enzymatic action than natural neuropeptides.

    In plain wordsIn rats, GWS-111 showed greater resistance to enzymatic action than natural neuropeptides.

    Peptide
    Noopept (omberacetam)
    Outcome
    IncreaseResistance to enzymatic action
    Study

    ratn: not reported in source

    Rat pharmacokinetics
    Comparator
    Natural neuropeptides
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    The compound under study showed a greater resistance to an enzymatic effect than natural neuropeptides.
    1 context sentence
    Summary · context
    The pharmacokinetics of a new nootropic dipeptide analog of piracetam-N-phenylacetyl-L-prolylglycine (GWS-111) and its main metabolites were studied in rats by means of high performance liquid chromatography and gas-liquid chromatography.

    In this study, Noopept (omberacetam) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Noopept (omberacetam).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.